iCanCope With Sickle Cell Pain
Status: | Recruiting |
---|---|
Conditions: | Anemia |
Therapuetic Areas: | Hematology |
Healthy: | No |
Age Range: | 12 - 18 |
Updated: | 5/3/2018 |
Start Date: | January 1, 2018 |
End Date: | December 2022 |
Contact: | Tonya M Palermo, PhD |
Email: | tonya.palermo@seattlechildrens.org |
Phone: | 206-884-4208 |
iCanCope With Sickle Cell Disease: A Mobile Pain Management Intervention for Adolescents
The project will test a tailored web and smartphone-based application (iCanCope with SCD) to
improve pain self-management and functioning in youth (aged 12-18) with sickle cell disease.
The program will include goal setting, peer-based social support, and pain self-management
training. The investigators will determine initial program effectiveness through a pilot
three-site randomized controlled trial in 160 youth randomized to treatment compared to
attention control.
improve pain self-management and functioning in youth (aged 12-18) with sickle cell disease.
The program will include goal setting, peer-based social support, and pain self-management
training. The investigators will determine initial program effectiveness through a pilot
three-site randomized controlled trial in 160 youth randomized to treatment compared to
attention control.
Cognitive-behavioral therapies (CBT) that promote pain self-management can lead to symptom
reduction, improved quality of life, and decreased healthcare use. However, most people with
SCD do not receive CBT-based treatment due to barriers such as poor accessibility, limited
availability of professionals, and high costs. First, the investigators plan to apply a
user-centered design approach to develop and refine the iCanCope with SCD program. Second,
program feasibility and initial program effectiveness will be determined through a pilot
three-site randomized controlled trial. The investigators will determine study accrual and
dropout rates as well as levels of patient acceptability and engagement. Preliminary
effectiveness will be determined in youth receiving treatment compared to attention control
on a range of physical, behavioral, and psychosocial outcomes assessed at post-treatment and
6-month follow-up. Third, moderators and mediators of treatment effect will be tested by
examining whether differences in self-efficacy and patient activation predict changes in pain
and functioning. These results will enable a future full-scale randomized controlled trial.
reduction, improved quality of life, and decreased healthcare use. However, most people with
SCD do not receive CBT-based treatment due to barriers such as poor accessibility, limited
availability of professionals, and high costs. First, the investigators plan to apply a
user-centered design approach to develop and refine the iCanCope with SCD program. Second,
program feasibility and initial program effectiveness will be determined through a pilot
three-site randomized controlled trial. The investigators will determine study accrual and
dropout rates as well as levels of patient acceptability and engagement. Preliminary
effectiveness will be determined in youth receiving treatment compared to attention control
on a range of physical, behavioral, and psychosocial outcomes assessed at post-treatment and
6-month follow-up. Third, moderators and mediators of treatment effect will be tested by
examining whether differences in self-efficacy and patient activation predict changes in pain
and functioning. These results will enable a future full-scale randomized controlled trial.
Inclusion Criteria:
- aged between 12-18 years
- diagnosed with any type of SCD
- able to speak and read English
- score at least 4 (indicating some days with pain interference over the past month) on
the Sickle Cell Pain Burden Interview
- willing and able to complete online measures
Exclusion Criteria:
- significant cognitive limitations that would impair their ability to use and
understand the iCanCope with SCD program, as per their healthcare provider or parent
- have previously received more than 4 sessions of outpatient psychological therapy for
pain management in the 6 months prior to the time of screening.
We found this trial at
4
sites
282 Washington St
Hartford, Connecticut 06106
Hartford, Connecticut 06106
(860) 545-9000
Principal Investigator: William Zempsky, MD
Connecticut Children's Medical Center Connecticut Children’s Medical Center is a nationally recognized, 187-bed not-for-profit children’s...
Click here to add this to my saved trials
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
Click here to add this to my saved trials
4800 Sand Point Way NE
Seattle, Washington 98105
Seattle, Washington 98105
(206) 987-2000
Principal Investigator: Tonya M Palermo, PhD
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
Click here to add this to my saved trials
Click here to add this to my saved trials